$ERO

'Big Short' Michael Burry Tunes Out AI ‘Woo-Hoos’ — Finds Opportunity In Copper, QXO And 3 More Stocks

Michael Burry, known for 'The Big Short,' has invested in Ero Copper (ERO), QXO (QXO), Temple & Webster, Sprouts Farmers Market (SFM), and Zoetis (ZTS), avoiding the AI trend. He sees value in copper due to supply-demand imbalances and expects Ero's margins to expand. QXO's preferred shares offer a 7.4% yield. Temple & Webster's revenue grew 11% in FY2026, while SFM and ZTS have declined significantly.

Original reporting
Published Sep 22, 2026, 2:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 2:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ERO
Bullish
medium confidence
Mentioned
$ERO · $QXO · $SFM · $ZTS
Relevance
6/10
AlphAI data visualization · based on stocktwits.com
Decision brief

The 30-second read

$EROBullishLow
01

Why it matters

His statements may shift sentiment toward undervalued copper and distressed consumer stocks, but overall market impact is limited.

02

Market read

Burry's new holdings provide a contrarian narrative to the AI‑driven rally, potentially influencing niche investors.

03

What to watch

Copper supply constraints and long‑term AI data‑center demand could drive sustained price appreciation.

Relevance 6/10Novelty 6/10Timing: today

Background

Michael Burry, famed from 'The Big Short', publicly shared his latest investment ideas via Substack, focusing on non‑AI themes.

Company-level read

Ticker impact

$EROBullishMedium confidence
Context

Michael Burry disclosed a new position in Ero Copper (ERO) citing its copper exposure for AI data centers.

Expected impact

Bullish pressure if copper rally continues; modest upside on news of Burry's backing.

Evidence & confidence

Burry's reputation may attract attention, but the company remains a small‑cap with limited liquidity.

$QXOBullishMedium confidence
Context

Burry revealed ownership of QXO common shares and its 5.5% Series B mandatory convertible preferred stock.

Expected impact

Short‑term rally possible as investors price in the preferred‑share yield.

Evidence & confidence

Burry's endorsement highlights undervaluation, but the stock is still volatile.

$SFMNeutralLow confidence
Context

Burry added a small position in Sprouts Farmers Market (SFM) after its 43% decline.

Expected impact

Minor upside if retail recovery materializes.

Evidence & confidence

Small position and broader retail challenges limit price move.

$ZTSNeutralLow confidence
Context

Burry disclosed a holding in Zoetis (ZTS), noting it is out of favor and down 50%.

Expected impact

Modest upside if investors view Burry's confidence as a catalyst.

Evidence & confidence

Zoetis is a large cap; Burry's stake is unlikely to move the market alone.

Market effects

Highlights potential undervaluation in copper and building‑products distribution sectors.

May boost interest in Brazil‑focused mining stocks and US building‑products distributors.

Burry's stance contrasts with the broader AI hype, offering contrarian themes.

Counterpoint

While AI hype dominates, Burry bets on commodity exposure and distressed consumer stocks.

Key entities

  • Michael Burry

    Investor known for contrarian bets, source of the disclosed positions.

  • Ero Copper Corp

    Brazil‑focused copper and gold miner (ticker ERO).

  • QXO

    Building‑products distribution roll‑up led by Brad Jacobs (ticker QXO).

Related articles

$ZTSMed

Can Zoetis Stock Jump 30%?

Zoetis (ZTS) stock is 45.1% below its 52-week high. The company's free cash yield is 6.8% of its market value, higher than the S&P 500 median. Zoetis faces challenges due to fewer pet vet visits and increased competition, leading to a revenue guidance cut. The stock trades at 12.9 times earnings, reflecting concerns about sustained cash flow growth and debt levels.

$ZTSMed

FDA approves Zoetis’ Convenia RTU for canine skin infections

Zoetis Inc. (ZTS) announced FDA approval for Convenia RTU for Dogs, a single-injection antibiotic for canine skin infections. The product offers 14 days of treatment in one dose and is expected to be available in Q1 2027. According to the company, the original Convenia has 18 years of real-world experience, with 86% of dogs resolving infections with one injection.

$ZTSMed

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

Zoetis received FDA approval for Convenia RTU for Dogs, a single-injection antibiotic treatment for bacterial skin infections in medium and large dogs. The product is expected to be available in Q1 2027, expanding Zoetis' dermatology portfolio and addressing compliance issues with oral antibiotics.

$ZTSHigh

Why is Zoetis stock sliding today?

Zoetis (ZTS) shares fell 1.4% premarket after Jefferies downgraded it to Hold, cutting its price target to $83 from $103. The firm cited risks to Zoetis's pricing power and lower earnings growth, projecting 2027 EPS to decline 2%. Jefferies also downgraded Elanco (ELAN) but kept a Buy rating on IDEXX (IDXX). U.S. pet product sales are declining, and vet visit volumes remain low.

$ZTSHigh

Jefferies downgrades Zoetis stock rating on pricing headwinds

Jefferies downgraded Zoetis (ZTS) to Hold from Buy, lowering its price target to $83 from $103. The firm cited concerns about pricing headwinds and lower volume growth, projecting a 2% decline in 2027 EPS. Jefferies also downgraded Elanco to Hold, citing pricing risks, while Fitch upgraded Elanco's ratings and Stifel reiterated a Buy rating.